Latest Posts Under: Pharma Industry News

Gilead Sciences to acquire immuno-oncology company Forty Seven for $4.9bn

Gilead Sciences acquisition of Forty Seven : US biotech company Gilead Sciences has signed an all-cash deal worth around $4.9 billion to acquire Forty Seven, a clinical-stage immuno-oncology company based in California, as per the latest pharma acquisition news. The immuno-oncology company is being acquired by Gilead Sciences for $95.50 per share in cash. Through […]

Antibe Therapeutics completes patient enrollment in OA knee pain trial for ATB-346

Antibe Therapeutics, a Canadian pharma company has completed enrollment of patients in a phase 2B dose-ranging, efficacy clinical trial of its lead drug candidate ATB-346 for its use in reducing osteoarthritis (OA) pain. The mid-stage clinical study will assess the effectiveness of ATB-346 in the reduction of OA knee pain in comparison to placebo in […]

Cerovene bags FDA approval for Daraprim generic for toxoplasmosis treatment

Cerovene has bagged approval from the US Food and Drug Administration (FDA) for its generic version of Daraprim (pyrimethamine) tablets for the treatment of toxoplasmosis when used with a sulfonamide, a group of medicines for bacterial infections. Toxoplasmosis is a foodborne infection caused by the parasite Toxoplasma gondii. A severe form of the condition can […]

Takeda Pharmaceutical acquires celiac disease drug developer PvP Biologics

Takeda acquisition of PvP Biologics : Japanese pharma giant Takeda Pharmaceutical Company has acquired US-based celiac disease drug developer PvP Biologics in a deal worth up to $330 million. The Japanese pharma major exercised its option to acquire the US pharma company following the completion of a phase 1 proof-of-mechanism study of the latter’s investigational […]

COSMIC-311 clinical trial : Exelixis enrolls patients to study cabozantinib in phase 3 thyroid cancer trial

COSMIC-311 clinical trial : US biotech company Exelixis has enrolled the first 100 patients in a phase 3 trial called COSMIC-311 for evaluating cabozantinib (CABOMETYX) against placebo in a type of thyroid cancer. The COSMIC-311 trial will feature patients having radioactive iodine-refractory differentiated thyroid cancer who have progressed following up to a couple of vascular […]

Cystic fibrosis drug KALYDECO to be launched in New Zealand by Vertex Pharmaceuticals

Vertex Pharmaceuticals is set to launch its cystic fibrosis drug KALYDECO (ivacaftor) in New Zealand, which will be available to eligible patients from next month. The US biopharma company said that clinicians can apply for patient access using the exceptional circumstances framework under the Pharmaceutical Management Agency (PHARMAC). Ludovic Fenaux – Senior Vice President of […]

ImmunoPrecise Antibodies launches vaccine development program for COVID-19

ImmunoPrecise Antibodies has launched a coronavirus vaccine development program to address the new coronavirus originating in Wuhan, China apart from developing coronavirus-neutralizing antibodies for addressing prophylactic and therapeutic measures to counter the virus and its associated disease, COVID-19. So far, COVID-19 has claimed the lives of nearly 1,875 people, while infecting more than 74,000 across […]

PADCEV, KEYTRUDA combination for advanced bladder cancer gets FDA breakthrough therapy status

PADCEV, KEYTRUDA combination : Astellas Pharma and Seattle Genetics said that the combination of PADCEV (enfortumab vedotin-ejfv) and Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) has been given breakthrough therapy designation from the US Food and Drug Administration (FDA) in first-line advanced bladder cancer. The FDA breakthrough therapy status for PADCEV, KEYTRUDA combination is for the treatment […]

Upsher-Smith Laboratories launches three generic drugs in US

Upsher-Smith Laboratories has launched three new products – Fluvoxamine Maleate Tablets, Clonidine Hydrochloride Extended-Release Tablets, and Haloperidol Tablets, USP, to expand its generic portfolio. According to the US pharma company, the market for the three generic drugs had combined sales of around $102.5 million in the US for the 12 months ending December 2019, as […]

Scroll To Top